Company intelligence / Profile preview

Pierrepont Therapeutics

Ownership: Private
Development stage: Preclinical

Overview

Developing PTI-501, a proprietary intracellular enzyme replacement therapy for MNGIE. Recently received $500,000 investment from The Mito Fund to advance this therapy into clinical development[4].

Therapeutic areas: Rare Diseases
Modalities: Enzyme replacement therapy
Industry: Biotech

Drug pipeline

1 asset

PTI-501

Preclinical

Partnerships

United Mitochondrial Disease Foundation (UMDF)Entrada Therapeutics, Inc.

Beyond the preview

Go deeper on Pierrepont Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pierrepont Therapeutics.

Explore the full profile